Juergen Thiele

TL;DR: The classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes.

TL;DR: In this paper, the authors proposed a revision of the current World Health Organization (WHO) diagnostic criteria for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), which was subsequently presented by an international expert panel of pathologists and clinical investigators in myeloproliferative disorders.

TL;DR: It is concluded that life expectancy in morphologically defined ET is significantly reduced but remains superior to that of PV, regardless of mutational status, and in PMF, JAK2/CALR/MPLmutational status is prognostically informative.

TL;DR: In multivariable analysis, survival for the entire study cohort was adversely affected by older age, leukocytosis, venous thrombosis and abnormal karyotype; a prognostic model delineated risk groups with median survivals of 10.9–27.8 years.

TL;DR: The authors, a group with expertise in the clinical, pathologic and genetic aspects of these disorders, developed the International Consensus Classification (ICC), aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.